Emerging retatrutide, a combined-action treatment targeting simultaneously GLP-1 and GIP receptors, is generating considerable interest within the healthcare community. Initial clinical studies have shown significant decreases in body weight and gains in metabolic markers for people with excess weight . Experts believe this unique approach could ma